References
Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054–1061.
Campbell PJ, Scott LM, Buck G, Wheatley K, East CL, Marsden JT et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet 2005; 366: 1945–1953.
Moliterno AR, Williams DM, Rogers O, Spivak JL . Molecular mimicry in the chronic myeloproliferative disorders: reciprocity between quantitative JAK2 V617F and Mpl expression. Blood 2006; 108: 3913–3915.
Passamonti F, Rumi E, Pietra D, Della Porta MG, Boveri E, Pascutto C et al. Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders. Blood 2006; 107: 3676–3682.
Wolanskyj AP, Lasho TL, Schwager SM, McClure RF, Wadleigh M, Lee SJ et al. JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance. Br J Haematol 2005; 131: 208–213.
el Kassar N, Hetet G, Briere J, Grandchamp B . Clonality analysis of hematopoiesis in essential thrombocythemia: advantages of studying T lymphocytes and platelets. Blood 1997; 89: 128–134.
Kiladjian JJ, Elkassar N, Cassinat B, Hetet G, Giraudier S, Balitrand N et al. Essential thrombocythemias without V617F JAK2 mutation are clonal hematopoietic stem cell disorders. Leukemia 2006; 20: 1181–1183.
Antonioli E, Guglielmelli P, Pancrazzi A, Bogani C, Verrucci M, Ponziani V et al. Clinical implications of the JAK2 V617F mutation in essential thrombocythemia. Leukemia 2005; 19: 1847–1849.
Acknowledgements
This research was supported by a grant from the Myeloproliferative Disorders Foundation and Grants RO1-HL 082995 and PO1-CA108671 from the National Institutes of Health and Grant MPO 48019 from the Department of Defense.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Pemmaraju, N., Moliterno, A., Williams, D. et al. The quantitative JAK2 V617F neutrophil allele burden does not correlate with thrombotic risk in essential thrombocytosis. Leukemia 21, 2210–2212 (2007). https://doi.org/10.1038/sj.leu.2404755
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2404755
- Springer Nature Limited
This article is cited by
-
Is there a gender effect in polycythemia vera?
Annals of Hematology (2021)
-
Next-generation sequencing for JAK2 mutation testing: advantages and pitfalls
Annals of Hematology (2019)
-
Patient characteristics and outcomes in adolescents and young adults with classical Philadelphia chromosome-negative myeloproliferative neoplasms
Annals of Hematology (2018)
-
Polycythemia Vera
Current Treatment Options in Oncology (2018)
-
Correlation between JAK2 allele burden and pulmonary arterial hypertension and hematological parameters in Philadelphia negative JAK2 positive myeloproliferative neoplasms. An Egyptian experience
Annals of Hematology (2016)